Rchr
J-GLOBAL ID:201801015753676339   Update date: Sep. 15, 2023

UEDA TOMOAKI

UEDA TOMOAKI
Affiliation and department:
Research keywords  (1): 造血幹細胞
Research theme for competitive and other funds  (3):
  • 2021 - 2024 白血病幹細胞の不均一性を誘導する自律的サイトカインシグナルを標的とした治療開発
  • 2019 - 2022 造血幹細胞抗原ESAMの欠損が胎生期に致死的な赤血球造血不全をきたすメカニズム
  • 2018 - 2021 Innovation of new methods rejuvenating lymphopoietic activity in aged hematopoietic stem cells
Papers (38):
  • Tomoaki Ueda, Jiro Fujita, Yasuhiro Akazawa, Ai Kawamura, Takahiro Matsui, Akihisa Hino, Shinsuke Kusakabe, Takao Sudo, Kentaro Fukushima, Takafumi Yokota, et al. Successful Bridging to Allogeneic Hematopoietic Stem Cell Transplantation by Azacitidine and Venetoclax in a Case of Acute Myeloid Leukemia With t(3;3)(q21.3;q26.2) Developed Early After Orthotopic Heart Transplantation. Transplantation Proceedings. 2023
  • Ayami Senda, Hideaki Saito, Shinsuke Kusakabe, Koki Yoshida, Kumi Shibata, Shuhei Kida, Jun Toda, Akihisa Hino, Tomoaki Ueda, Jiro Fujita, et al. [Acquired hemophilia A following BNT162b2 mRNA COVID-19 vaccination]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2023. 64. 1. 35-41
  • Akihisa Hino, Kentaro Fukushima, Shinsuke Kusakabe, Tomoaki Ueda, Takao Sudo, Jiro Fujita, Daisuke Motooka, Aya K Takeda, Natsuko O Shinozaki, Satoshi Watanabe, et al. Prolonged gut microbial alterations in post-transplant survivors of allogeneic haematopoietic stem cell transplantation. British journal of haematology. 2022. 201. 4. 725-737
  • 芥田 敬吾, 福島 健太郎, 中田 継一, 林 悟, 堤 一仁, 日野 彬央, 戸田 淳, 草壁 信輔, 上田 智朗, 藤田 二郎, et al. 同種造血幹細胞移植後ITPの診断における網状血小板比率、抗血小板自己抗体測定の意義. 日本血栓止血学会誌. 2022. 33. 2. 288-288
  • Takayuki Ozawa, Kentaro Fujii, Takao Sudo, Yukiko Doi, Ritsuko Nakai, Yasuhiro Shingai, Tomoaki Ueda, Yoshihiro Baba, Naoki Hosen, Takafumi Yokota. Special AT-Rich Sequence-Binding Protein 1 Supports Survival and Maturation of Naive B Cells Stimulated by B Cell Receptors. The Journal of Immunology. 2022. 208. 8. 1937-1946
more...
MISC (71):
  • 村上拓, 水谷陽, 杉本彩乃, 遠藤誉也, 吉田好機, 町田朋久, 倉重隆明, 笠原秀範, 日野彬央, 草壁信輔, et al. Study of Lymphocyte Extraction and Treatment Outcomes in Kymriah for Relapsed/Refractory DLBCL. 日本造血・免疫細胞療法学会総会プログラム・抄録集. 2022. 45th
  • 水谷陽, 上田智朗, 福島健太郎, 杉本彩乃, 遠藤誉也, 村上拓, 吉田好機, 菅真紀子, 柴田久美, 中田継一, et al. Optimal treatment with Ibrutinib as a second-line treatment for steroid dependent/refractory cGVHD. 日本造血・免疫細胞療法学会総会プログラム・抄録集. 2022. 45th
  • 竹内 甲, 上田 智朗, 藤田 二郎, 福島 健太郎, 西村 純一, 保仙 直毅, 倉重 真沙子, 森井 英一. 卵巣がんに合併したホジキンリンパ腫の1例. 臨床血液. 2021. 62. 3. 208-208
  • 菅真紀子, 福島健太郎, 上田智朗, 吉田好機, 小池翠, 戸田淳, 芥田敬吾, 日野彬央, 土居由貴子, 長手泰宏, et al. Successful treatment of refractory FLT3-ITD acute myeloid leukemia with Quizartinib prior to CBT. 日本造血細胞移植学会総会プログラム・抄録集. 2021. 43rd
  • 吉田好機, 福島健太郎, 菅真紀子, 芥田敬吾, 上田智朗, 日野彬央, 土居由貴子, 長手泰宏, 藤田二郎, 横田貴史, et al. Bridging therapy to allogeneic stem cell transplantation with Inotuzumab/Blinatumomab for R/R Ph1ALL. 日本造血細胞移植学会総会プログラム・抄録集. 2021. 43rd
more...
Education (2):
  • 2014 - 2020 Osaka University Graduate School of Medicine Division of Medicine
  • 2001 - 2007 Osaka University Faculty of Medicine Medical School
Professional career (1):
  • 医学博士 (大阪大学)
Work history (5):
  • 2021/04 - 現在 Osaka University Graduate School of Medicine
  • 2014/04 - 2021/03 Osaka University Hospital
  • 2012/04 - 2014/03 倉敷中央病院 血液内科 専門修練医
  • 2009/04 - 2012/03 倉敷中央病院 血液内科 後期研修医
  • 2007/04 - 2009/03 住友病院 総合診療科 初期研修医
Awards (2):
  • 2018/12 - American Society of Hematology Abstract Achievement Award ESAM on the cells of endothelial lineage plays an important role in the development of definitive hematopoiesis
  • 2016/12 - American Society of Hematology Abstract Achievement Award Endothelial Cell-Selective Adhesion Molecule (ESAM) Is Required for the Ontogeny of Definitive Hematopoietic System in Mice
Association Membership(s) (5):
THE JAPAN SOCIETY OF TRANSFUSION MEDICINE AND CELL THERAPY ,  日本臨床腫瘍学会 ,  日本造血細胞移植学会 ,  THE JAPANESE SOCIETY OF HEMATOLOGY ,  THE JAPANESE SOCIETY OF INTERNAL MEDICINE
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page